

# Psycho-social treatment for people with psychosis in south eastern Europe

<b>Submission date</b> 21/03/2019	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 29/03/2019	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 05/02/2026	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

People with psychosis sometimes hear voices, and don't understand what is real and what is not, for example, they can think that family or friends are part of a conspiracy to harm them. They can also experience low mood, isolation and lack of hope and initiative. People with psychosis die 15-20 years earlier than other citizens due to under diagnosed physical illnesses, poor access to healthcare and suicide. In countries with low income up to 50% of people with psychosis do not receive care for their condition. Available treatment is largely focused on anti-psychotic medication which neglects people's social needs and resources. The aim of this study is to test a psycho-social treatment for people with psychosis in south eastern Europe.

### Who can participate?

Patients aged 18 or older with psychosis

### What does the study involve?

Participants are allocated by chance to either an intervention called Dialog+ or treatment as usual for 12 months. Dialog+ is used during routine clinical meetings. The clinician asks the patient to talk about their satisfaction with different areas of life, such as mental health, physical health, medication, family life, etc. In this way the patient identifies problems and in the next step the patient is guided by the clinician to identify solutions to these problems. Clinicians and patients use computer tablets to engage in this conversation. It is expected that Dialog+ will improve the quality of life and mental health of patients with psychosis.

### What are the possible benefits and risks of participating?

Possible benefits for patients include feeling less distressed and having better quality of life. No risks of participating have been reported. However, some participants might become upset due to recalling distressing personal experiences. Appropriate support will be provided to distressed individuals.

### Where is the study run from?

1. Universiteti i Prishtines (Kosovo)
2. Klinicki Centar Univerziteta U Sarajevu (Bosnia and Herzegovina)
3. Faculty of Medicine, University of Belgrade (Serbia)

4. University Clinic of Psychiatry Skopje (Macedonia)
5. Clinical Centre of Montenegro (Montenegro)

When is the study starting and how long is it expected to run for?  
April 2019 to June 2020

Who is funding the study?  
European Commission

Who is the main contact?  
1. Tamara Pemovska  
t.pemovska@qmul.ac.uk  
2. Dr Nikolina Jovanovic  
n.jovanovic@qmul.ac.uk

## Contact information

**Type(s)**  
Public

**Contact name**  
Miss Tamara Pemovska

**Contact details**  
Queen Mary University of London  
NCFMH  
Academic Unit  
Glen Road  
London  
United Kingdom  
E13 8SP  
+44 (0)20 7540 4380 x 2330  
t.pemovska@qmul.ac.uk

**Type(s)**  
Scientific

**Contact name**  
Dr Nikolina Jovanovic

**ORCID ID**  
<https://orcid.org/0000-0002-7554-9837>

**Contact details**  
Queen Mary University of London  
NCFMH  
Academic Unit  
Glen Road  
London  
United Kingdom  
E13 8SP

+44 (0)20 7540 4380  
n.jovanovic@qmul.ac.uk

## **Additional identifiers**

**Protocol serial number**  
779334

## **Study information**

### **Scientific Title**

Implementation of an effective and cost-effective intervention for patients with psychotic disorders in low and middle income countries in south eastern Europe

### **Acronym**

IMPULSE

### **Study objectives**

The intervention (Dialog+) is effective in reducing clinical symptoms, improving quality of life and in reducing treatment costs for people with psychosis.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Approved 16/10/2018, Queen Mary Ethics of Research Committee (Queen Mary, University of London, Room W117, Queen's Building, Mile End Road, London E1 4NS; Tel: +44 (0)20 7882 7915; Email: h.covill@qmul.ac.uk), ref: QMREC2204a

The study has been approved by institutional ethics committees in all participating countries: Bosnia and Herzegovina (Klinicki Centar Univerziteta U Sarajevu), Former Yugoslav Republic of Macedonia (University Clinic Of Psychiatry, Skopje), Kosovo (Universiteti I Prishtines), Montenegro (Clinical Centre Of Montenegro, Podgorica), and Serbia (Klinicki Centar Univerziteta U Beogradu).

### **Study design**

Hybrid type 2 effectiveness/implementation, multi-centre study; effectiveness will be studied in a pragmatic, parallel-group, cluster-randomized controlled trial

### **Primary study design**

Interventional

### **Study type(s)**

Treatment

### **Health condition(s) or problem(s) studied**

Psychosis

### **Interventions**

After baseline assessments, clinicians will be randomized to the intervention (DIALOG+ for 12 months) or control (TAU for 12 months), with an allocation ratio of 1:1.

The intervention group will receive DIALOG+, an evidence-based, technology-assisted intervention designed to make routine meetings between clinicians and patients patient-centred, structured and more therapeutically effective.

The control group will include routine meetings offering treatment as usual. This includes consultations on medication, psychological support and discussion on other aspects of care. After 12 months, clinicians in the control groups will be trained to deliver DIALOG+ and the intervention will be offered to patients in the control group.

## **Intervention Type**

Mixed

## **Primary outcome(s)**

Subjective quality of life measured by Manchester Short Assessment of Quality of Life (MANSA) at baseline, 6 months and 12 months

## **Key secondary outcome(s)**

Measured at baseline, 6 months and 12 months:

1. Treatment satisfaction measured using Client Satisfaction Questionnaire (CSQ)-8
2. Clinical symptoms measured using Brief Symptom Inventory (BSI), Brief Psychiatric Rating Scale (BPRS), and Clinical Assessment Interview for Negative Symptoms (CAINS)

## **Completion date**

26/06/2020

# **Eligibility**

## **Key inclusion criteria**

Clinicians:

1. Having a professional qualification in mental health care
2. More than 6 months' experience of working in mental health care
3. No plans to leave their post within the study period

Patients:

1. Primary diagnosis of psychosis or related disorder (i.e.: ICD-10 F20-29, F31)
2. Aged 18 years or older
3. Attending the outpatient clinic or day hospital
4. History of at least one hospital admission in their lifetime
5. There should not be plans to be discharged from mental health care services for the next 12 months
6. Capacity to provide informed consent

## **Healthy volunteers allowed**

No

## **Age group**

Mixed

**Lower age limit**

18 years

**Upper age limit**

99 years

**Sex**

All

**Total final enrolment**

549

**Key exclusion criteria**

Clinicians:

1. No exclusion criteria

Patients:

1. Having a diagnosis of organic brain disorders

2. Having severe cognitive deficits (unable to provide information to study instruments). This will be based on the clinical judgement

**Date of first enrolment**

01/02/2019

**Date of final enrolment**

01/09/2019

**Locations****Countries of recruitment**

Bosnia and Herzegovina

Kosovo

Montenegro

North Macedonia

Serbia

**Study participating centre**

Universiteti i Prishtines

Street Nena Tereze

Prishtina

Kosovo

10000

**Study participating centre**  
**Klinicki Centar Univerziteta U Sarajevu**  
Bolnicka 25  
Sarajevo  
Bosnia and Herzegovina  
71000

**Study participating centre**  
**Faculty of Medicine, University of Belgrade**  
Dr Subotica, 8  
Belgrade  
Serbia  
11000

**Study participating centre**  
**University Clinic of Psychiatry Skopje**  
Belgradska b.b.  
Skopje  
North Macedonia  
10000

**Study participating centre**  
**Clinical Centre of Montenegro**  
Ljubljanska bb  
Podgorica  
Montenegro  
81000

## **Sponsor information**

**Organisation**  
European Commission, Directorate-General for Research and Innovation

**ROR**  
<https://ror.org/01ef4as46>

## **Funder(s)**

**Funder type**

Government

### Funder Name

European Commission

### Alternative Name(s)

European Union, Comisión Europea, Europäische Kommission, EU-Kommissionen, Euroopa Komisjoni, EC, EU

### Funding Body Type

Government organisation

### Funding Body Subtype

National government

### Location

## Results and Publications

### Individual participant data (IPD) sharing plan

Anonymised dataset will be available on request from April 2021. Requests can be sent to Dr Nikolina Jovanovic, (n.jovanovic@qmul.ac.uk). The researchers will not share analysed data as they want to have them published in an open access peer reviewed journal. All patients and clinicians participating in the study signed informed consent approved by the relevant ethics committees.

### IPD sharing plan summary

Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>		01/01/2020	20/09/2021	Yes	No
<a href="#">Basic results</a>		21/01/2022	21/01/2022	No	No
<a href="#">Interim results article</a>	Physical health of individuals with psychosis - a mixed method study	16/01/2023	17/01/2023	Yes	No
<a href="#">Other publications</a>	Economic evaluation	26/08/2022	08/04/2024	Yes	No
<a href="#">Other publications</a>	Process evaluation	04/02/2026	05/02/2026	Yes	No
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes